BioCryst to Present at Upcoming Investor Conference

Rhea-AI Summary

BioCryst Pharmaceuticals (Nasdaq: BCRX) announced participation in the 21st Annual Needham Virtual Healthcare Conference on April 14, 2022, at 11:45 a.m. ET. A live audio webcast and replay will be accessible in the Investors & Media section of BioCryst’s website. The company focuses on discovering novel oral medicines for rare diseases, with products like ORLADEYO® approved in multiple regions. BioCryst also has ongoing programs for complement-mediated diseases and viral infections.

News Market Reaction – BCRX

-2.16%

-2.16% Session move

In the trading session that priced this news, BCRX declined 2.16%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

RESEARCH TRIANGLE PARK, N.C., April 11, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 21^st Annual Needham Virtual Healthcare Conference on Thursday, April 14, 2022, at 11:45 a.m. ET.

Links to a live audio webcast and replay of the presentation may be accessed in the Investors & Media section of BioCryst’s website at http://www.biocryst.com.

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO^® (berotralstat) is approved in the United States, the European Union, Japan, the United Kingdom and the United Arab Emirates. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB^® (peramivir injection) has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the company’s website at www.biocryst.com.

BCRXW

Investor Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com

Media Contact:
Catherine Collier Kyroulis
+1 917 886 5586
ckyroulis@biocryst.com 

FAQ

What is the date and time of BioCryst's presentation at the Needham Conference?

BioCryst Pharmaceuticals will present at the Needham Virtual Healthcare Conference on April 14, 2022, at 11:45 a.m. ET.

Where can I watch BioCryst's conference presentation?

You can access the live audio webcast of BioCryst's presentation in the Investors & Media section of their website.

What products does BioCryst Pharmaceuticals focus on?

BioCryst specializes in oral medicines for rare diseases, including ORLADEYO® for hereditary angioedema.

What ongoing development programs does BioCryst have?

BioCryst has ongoing programs for BCX9930, BCX9250, and galidesivir targeting various diseases.

What is the stock symbol for BioCryst Pharmaceuticals?

The stock symbol for BioCryst Pharmaceuticals is BCRX.